Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Cha...
Collaboration leverages Tenacia’s CNS, R&D, and local market expertise to support expansion of ganaxolone’s development programs and potentially provide additional access to patients globally Marinus to receive an upfront fee of $10 million and eligible t...
Penny Stocks With Unusual Options Activity When it comes to trading penny stocks, options usually don’t initially come to mind for new traders. Most new traders will choose to buy options because higher-priced stocks are too expensive. The options contracts are much cheaper. ...
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Sasha Damouni Ellis – Vice President-Corporate Affairs and Investor Relations Scott Braunstein – Chief Executive Officer Christy S...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Marinus Pharmaceuticals ( NASDAQ: MRNS ) stock dropped 18% after-hours on Monday after the firm has priced its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75/share, and, to certain investors in lieu ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price ...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) stock dropped 19% postmarket on Monday after the firm announced an underwritten public offering of its securities. Underwriters will have a 30-day option to buy up to an additional 15% of the number of securities in the off...
Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q3 EPS of $1.89 may not be comparable to consensus of $0.02. Revenue of $2.34M (-76.9% Y/Y) misses by $23.42M . Shares -20% . For further details see: Marinus PharmaceuticalsEPS of $1.89, revenue...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the off...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus P...